| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8713497 | Journal of Allergy and Clinical Immunology | 2018 | 33 Pages |
Abstract
A strong body of evidence supports the use of omalizumab in the treatment of patients with therapy-refractory CIndU. More data from randomized controlled studies are warranted.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Marcus MD, Martin MD, Randolf MD, Uwe MD, Thilo MD, Vera MD, Claudia MD, Petra MD, Regina MD, Bettina MD, Markus MD,